Digestive Diseases and Sciences

, Volume 59, Issue 7, pp 1535–1543 | Cite as

Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease

  • Seth D. Crockett
  • Robin Schectman
  • Til Stürmer
  • Michael D. Kappelman
Original Article



Additional medications are needed for inflammatory bowel disease (IBD) as existing therapies are incompletely effective and can be costly and toxic. Preclinical studies suggest that topiramate (an anticonvulsant) may have disease-modifying properties in IBD, but its efficacy in humans is unknown.


To evaluate whether topiramate use is associated with clinical benefit in IBD patients.


We conducted a retrospective cohort study using administrative claims data from the MarketScan databases. Persons with IBD were identified between 2000 and 2010. New users of topiramate were compared with users of other anticonvulsant and anti-migraine medications. The primary outcome was a new prescription for an oral steroid (≥14 days). Secondary outcomes included initiation of biologic agents, abdominal surgery, and hospitalization. Cox proportional hazard modeling was used to adjust for potential confounders.


We identified 773 new users of topiramate and 958 users of comparator drugs. After adjusting for potential confounders, topiramate use was not associated with the primary outcome of steroid prescriptions [hazard ratio (HR) 1.14, 95 % confidence interval (CI) 0.74, 1.73]. Results did not differ significantly by IBD subtype. There was no difference between topiramate users and users of comparator drugs with respect to post-exposure initiation of biologic agents (HR 0.93, 95 % CI 0.39, 2.19), abdominal surgery (HR 1.04, 95 % CI 0.17, 6.41), or hospitalization (HR 0.86, 95 % CI 0.62, 1.19).


In this large U.S. administrative claims study, topiramate use was not associated with markers of IBD flares. These results cast doubt on whether topiramate may be an effective adjunct to current IBD therapy.


Drug repositioning Ulcerative colitis Crohn disease Inflammatory bowel diseases Glucocorticoids Cohort studies 



Adjusted hazard ratios


Crohn’s disease


Confidence interval


Current procedural terminology code


U.S. Food and Drug Administration


Inflammatory bowel disease


Irritable bowel syndrome


International Classification of Diseases, 9th Revision, Clinical Modification




Ulcerative colitis


  1. 1.
    Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103:1998–2006.PubMedCrossRefGoogle Scholar
  2. 2.
    Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.PubMedCrossRefGoogle Scholar
  3. 3.
    Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438.PubMedCrossRefGoogle Scholar
  4. 4.
    Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978;1:1140–1143.PubMedGoogle Scholar
  5. 5.
    Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:1135–1140.PubMedCrossRefGoogle Scholar
  6. 6.
    Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003;125:1583–1590.PubMedCrossRefGoogle Scholar
  7. 7.
    Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.PubMedCrossRefGoogle Scholar
  9. 9.
    Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform. 2011;12:346–356.PubMedCrossRefGoogle Scholar
  10. 10.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  11. 11.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397–1404.PubMedCrossRefGoogle Scholar
  12. 12.
    Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157.PubMedCrossRefGoogle Scholar
  13. 13.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.PubMedCrossRefGoogle Scholar
  14. 14.
    Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med. 2008;358:2787–2795.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3:96ra76.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104:1445–1451.PubMedCrossRefGoogle Scholar
  17. 17.
    Loftus EV Jr, Delgado DJ, Friedman HS, Sandborn WJ. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103:1737–1745.PubMedCrossRefGoogle Scholar
  18. 18.
    Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481–485.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA. 2005;294:797–802.PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26:1847–1851.PubMedCrossRefGoogle Scholar
  21. 21.
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.PubMedCrossRefGoogle Scholar
  22. 22.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.PubMedCrossRefGoogle Scholar
  23. 23.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.PubMedCrossRefGoogle Scholar
  24. 24.
    Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–740.PubMedGoogle Scholar
  25. 25.
    Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004;126:665–673.PubMedCrossRefGoogle Scholar
  26. 26.
    Goodman MJ, Durkin M, Forlenza J, Ye X, Brixner DI. Assessing adherence-based quality measures in epilepsy. Int J Qual Health Care. 2012;24:293–300.PubMedCrossRefGoogle Scholar
  27. 27.
    Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007;13:451–461.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Seth D. Crockett
    • 1
  • Robin Schectman
    • 2
  • Til Stürmer
    • 3
  • Michael D. Kappelman
    • 4
  1. 1.Division of Gastroenterology and HepatologyUniversity of North CarolinaChapel HillUSA
  2. 2.Cecil G. Sheps Center for Health Services ResearchUniversity of North CarolinaChapel HillUSA
  3. 3.Department of Epidemiology, Gillings School of Global Public HealthUniversity of North CarolinaChapel HillUSA
  4. 4.Division of Pediatric GastroenterologyUniversity of North Carolina School of MedicineChapel HillUSA

Personalised recommendations